Diseases myeloproliferative

Wang J, Iwasaki H, Krivtsov A, Febbo PG, Thorner AR, Ernst P, Anastasiadou E, Kutok JL, Kogan SC, Zinkel SS., Fisher, JK, Hess, JL, Golub TR, Armstrong SA, Akashi K, Korsmeyer SJ (2005) Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. EMBO J... 

Lysis of formed blood elements other than erythrocytes may produce elevations in serum or plasma constituents. Platelet breakdown during blood collection can introduce enzymes into the plasma (Z3). Aldolase activity is very high in platelets (Dl), and elevations of acid phosphatase in myeloproliferative disease are probably the result of platelet lysis (B6). 

B6. Bases, R., Elevations of serum acid phosphatase in certain myeloproliferative diseases. New Engl. J. Med. 266, 538-540 (1962). 

Ludwig, H., A. Cortelezzi, B.G. Van Camp, E. Polli, W. Scheithauer, R. Kuzmits, W. Linkesch, H. Gisslinger, H. Sinzinger, E. Eritz, et al.. Treatment with recombinant interferon-alpha-2C multiple myeloma and thrombocythaemia in myeloproliferative diseases. Oncology, 1985. 42(Suppl 1) 19-25. 

Gilbert, H.S., Long term treatment of myeloproliferative disease with interferon-alpha-2b feasibility and efficacy. Cancer, 1998. 83(6) 1205-13. 

Inokuchi, K., Dan, K., Takatori, M., Takahuji, H., Uchida, N., Inami, M., et al. (2003) Myeloproliferative disease in transgenic mice expressing P230 Bcr/Abl longer disease latency, thrombocytosis, and mild leukocytosis. Blood 102, 320-323. 

Said, J. W., Stoll, P. N., Shintaku, P., Bindl, J. M., Butmarc, J. R., and Pinkus, G. S., Leu-22 A preferential marker for T-lymphocytes in paraffin sections. Staining profile in T- and B-cell lymphomas, Hodgkin s disease, other lymphoproliferative disorders, myeloproliferative diseases, and various neoplastic processes. Am. J. Clin. Pathol. 91, 542-549 (1989). 

Wahlstrom, A.M., et al. (2008). Inactivating Icmt ameliorates K-RAS-induced myeloproliferative disease. Blood 112 1357-1365. 

Chan, I.T., et al. (2004). Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest 113 528-538. 

Bergo and colleagues have also recently described the effect of GGT-1 deficiency in the hematopoietic system [38]. Mice harboring an inducible oncogene in hematopoietic cells develop a lethal myeloproliferative disease (MPD), and up to a third also develop acute lymphoblastic leukemia (ALL). Whereas the absence of GGT-1 markedly reduces the severity of MPD, it has no impact on ALL [38]. Since KRAS can be farnesylated in the absence of GGT-1, the antitumor effects of GGT-1 depletion with regards to MPD can be attributed to defective prenylation of GGT-1 targets [38] downstream of KRAS, for example, RALA and RALB. 

Sjogren, A.K., Andersson, K.M., Khan, O., Olofsson, F.J., Karlsson, C., and Bergo, M.O. (2011). Inactivating GGTase-I reduces disease pheuotypes iu a mouse model of K-RAS-induced myeloproliferative disease. Leukemia 25 186-189. 

Acquired platelet function defects have been associated with several canine diseases. Decreased platelet aggregation responses have been reported for dog with liver disease, pancreatitis, myeloproliferative disease, and ehrlichiosis (Harms et al. 1996 Willis et at. 1989). 

Each laparoscopy should aim at a visual assessment of the spleen in terms of (7.) size, (2.) colour, (i.) shape, and (4.) identifiable spleen diseases. Special mention should be made of capsular fibrosis, hyalinosis ( sugar-coated spleen ), tumours (e. g. Hodgkin s disease, retothelial sarcoma), tuberculosis, splenic cysts, splenic infarction (s. fig. 35.10) and splenic haematoma. Given appropriate positioning, the spleen is visible in 80% of cases. In the case of myeloproliferative diseases, a biopsy of the spleen (e. g. by means of the Menghini technique) can provide a definitive diagnosis, (s. pp 135,253) (s. figs. 11.1 14.7) (see chapter 11)... 

Examples of secondary malignant liver tumours are (i.) liver metastases, (2.) myeloid metaplasia, (S.) myeloproliferative diseases, and (4.) lymphomatosis. 

Men and women are affected with the same frequency at almost any age. Familial forms have been described. (63) There is an association with polyarthritis, coeliac disease (58), PSC, PBC (61), sarcoidosis, Budd-Chiari syndrome, and collagenoses or myeloproliferative diseases. A connection with thorotrast (59), immunosuppressives, cytostatics and contraceptives or androgens as... 

Fig. 38.1 Extramedullary haemopoiesis in the liver with erythro-poiesis precursors and intrasinusoidal megakaryocyte ( ) due to the so-called marrow-replacement syndrome or chronic myeloproliferative disease (HE)...

Anger, B.R., Seifried, E., Scheppach, J., Heimpel, H. Budd-Chiari syndrome and thrombosis of other abdominal vessels in chronic myeloproliferative diseases. Klin. Wschr. 1989 67 818 -825... 

Lupus anticoagulant Myeloproliferative disease (31) Paroxysmal nocturnal haemoglobinuria Polycythaemia vera Protein C deficiency (68)... 

The slight but definite elevations of serum acid phosphatase activity in conditions such as thrombocytopenia (02, Zl), Gaucher s disease (T6, T8), or various myeloproliferative diseases (B6) indicate the possibility that platelets, the marrow, and the reticuloendothelial system may also be sources of acid phosphatase. These aspects will be discussed more fully later in the review. 

Serum Acid Phosphatase Activity in Other Myeloproliferative Disease... 

Yl. Yu, T. F., Secondary gout associated with myeloproliferative diseases. Arthritis Rheumat. 8, 765-771 (1965). 

Drugs Alcohol, estrogens, isotretinoin, beta blockers, glucocorticoids, bile-acid resins, thiazides asparaginase, interferons, azole antifungals, mirtazapine, anabolic steroids, sirolimus, bexarotene Malnutrition Malabsorption Myeloproliferative diseases Chronic infectiousdiseases AIDS, tuberculosis Monoclonal gammopathy Chronic liver disease Malnutrition Obesity... 

---